ARTICLE | Company News
Complete response for Forest's cariprazine
November 22, 2013 1:24 AM UTC
FDA issued a complete response letter for an NDA from Forest Laboratories Inc. (NYSE:FRX) for cariprazine ( RGH-188; MP-214) to treat schizophrenia and manic or mixed episodes associated with bipolar ...